Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

التفاصيل البيبلوغرافية
العنوان: Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
المؤلفون: Yizhen Guo, Lai Wei, Sandip H. Patel, Gabrielle Lopez, Madison Grogan, Mingjia Li, Tyler Haddad, Andrew Johns, Latha P. Ganesan, Yiping Yang, Daniel J. Spakowicz, Peter G. Shields, Kai He, Erin M. Bertino, Gregory A. Otterson, David P. Carbone, Carolyn Presley, Samuel K. Kulp, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps, Dwight H. Owen
المصدر: Clin Lung Cancer
سنة النشر: 2022
مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, Oncology, Carcinoma, Non-Small-Cell Lung, Humans, Prognosis, Immune Checkpoint Inhibitors, Article, Serum Albumin, Retrospective Studies
الوصف: MICROABSTRACT: Serum albumin in cancer patients is associated with clinical outcomes. In a single-center retrospective study of 210 advanced NSCLC patients receiving immune checkpoint inhibitor (ICI) with or without chemotherapy as first-line therapy, we found a significant association of overall survival with pretreatment albumin and early albumin decrease in treatment with ICI monotherapy but not with chemoimmunotherapy. BACKGROUND: Cancer cachexia exhibits decreased albumin and associates with short overall survival (OS) in patients with non-small cell lung cancer (NSCLC), but whether on-treatment albumin changes associate with OS in NSCLC patients treated with immune checkpoint inhibitors (ICIs) and combination chemoimmunotherapy has not been thoroughly evaluated. PATIENTS AND METHODS: We conducted a single-center retrospective study of patients with advanced NSCLC who received first-line ICI with or without chemotherapy between 2013 and 2020. The association of pretreatment albumin and early albumin changes with OS was evaluated using Kaplan-Meier method and Cox regression models. RESULTS: A total of 210 patients were included: 109 in ICI cohort and 101 in ICI+Chemo cohort. Within a median of 21 days from treatment initiation, patients with ≥10% of albumin decrease had significantly shorter OS compared to patients without albumin decrease in ICI cohort. Pretreatment albumin and albumin decrease within the first or second cycle of treatment were significantly and independently associated with OS in ICI cohort, but not in ICI+Chemo cohort. The lack of association between albumin and OS with the addition of chemotherapy was more pronounced among patients with ≥ 1% PD-L1 expression in subgroup analysis. CONCLUSION: Pretreatment serum albumin and early albumin decrease in ICI monotherapy was significantly associated with OS in advanced NSCLC. Early albumin change, as a routine lab value tested in clinic, may be combined with established biomarkers to improve outcome predictions of ICI monotherapy. The underlying mechanism of the observed association between decreased albumin and ICI resistance warrants further investigation.
اللغة: English
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be19bfce21a04ebb6945272592627ee6
https://europepmc.org/articles/PMC9149057/
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....be19bfce21a04ebb6945272592627ee6
قاعدة البيانات: OpenAIRE